Sena Kurita
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Journal: BMC veterinary research
Published: December 07, 2020
Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.
Journal: Journal of the American Animal Hospital Association
Published: March 18, 2020
The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Journal: BMC veterinary research
Published: July 17, 2019
Genetic alterations of KIT during clonal expansion and subsequent acquisition of resistance to toceranib in a canine mast cell tumor cell line.
Journal: Journal of veterinary pharmacology and therapeutics
Published: May 26, 2019
Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Journal: Veterinary and comparative oncology
Published: April 04, 2019
A genetic variant of CYP2R1 identified in a cat with type 1B vitamin D-dependent rickets: a case report.
Journal: BMC veterinary research
Published: March 27, 2018
Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
Journal: Veterinary journal (London, England : 1997)
Published: February 09, 2018
Establishment and characterization of a cell line from a feline histiocytic sarcoma.
Journal: Veterinary immunology and immunopathology
Published: May 23, 2017
Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Journal: Journal of veterinary pharmacology and therapeutics
Published: April 07, 2017
A decrease in ubiquitination and resulting prolonged life-span of KIT underlies the KIT overexpression-mediated imatinib resistance of KIT mutation-driven canine mast cell tumor cells.
Journal: Oncology reports
Published: March 24, 2017
Selective growth inhibition by suppression of F1Fo ATPase in canine malignant melanoma cell lines.
Journal: Journal of veterinary pharmacology and therapeutics
Published: March 22, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026